STOCK TITAN

Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the 2021 Jefferies Virtual Healthcare Conference, being held June 1 - 4, 2021.

Details on the Jefferies fireside chat presentation are as follows:

 Title: 2021 Jefferies Virtual Healthcare Conference
    
 Presenters: Vipin Garg, Ph.D., Chief Executive Officer
   Scot Roberts, Ph.D., Chief Scientific Officer
   Scott Harris, M.D., Chief Medical Officer
    
 Date/Time: Wednesday, June 2, 2021 at 11:30 am ET

A webcast link to the fireside chat presentation will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Investor & Media Contacts:  
   
Will Brown Stacey Jurchison
Chief Financial Officer  Sr. Dir, Investor Relations
Phone: 240-654-1450 Phone : 410-474-8200
wbrown@altimmune.com sjurchison@altimmune.com


 


Altimmune, Inc.

NASDAQ:ALT

ALT Rankings

ALT Latest News

ALT Stock Data

453.38M
70.33M
0.78%
62.24%
25.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
GAITHERSBURG

About ALT

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current